 |
PDBsum entry 2bpi
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Oxidoreductase
|
PDB id
|
|
|
|
2bpi
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
The crystal structure of superoxide dismutase from plasmodium falciparum.
|
 |
|
Authors
|
 |
I.W.Boucher,
A.M.Brzozowski,
J.A.Brannigan,
C.Schnick,
D.J.Smith,
S.A.Kyes,
A.J.Wilkinson.
|
 |
|
Ref.
|
 |
Bmc Struct Biol, 2006,
6,
20.
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
BACKGROUND: Superoxide dismutases (SODs) are important enzymes in defence
against oxidative stress. In Plasmodium falciparum, they may be expected to have
special significance since part of the parasite life cycle is spent in red blood
cells where the formation of reactive oxygen species is likely to be promoted by
the products of haemoglobin breakdown. Thus, inhibitors of P. falciparum SODs
have potential as anti-malarial compounds. As a step towards their development
we have determined the crystal structure of the parasite's cytosolic iron
superoxide dismutase. RESULTS: The cytosolic iron superoxide dismutase from P.
falciparum (PfFeSOD) has been overexpressed in E. coli in a catalytically active
form. Its crystal structure has been solved by molecular replacement and refined
against data extending to 2.5 A resolution. The structure reveals a two-domain
organisation and an iron centre in which the metal is coordinated by three
histidines, an aspartate and a solvent molecule. Consistent with
ultracentrifugation analysis the enzyme is a dimer in which a hydrogen bonding
lattice links the two active centres. CONCLUSION: The tertiary structure of
PfFeSOD is very similar to those of a number of other iron-and
manganese-dependent superoxide dismutases, moreover the active site residues are
conserved suggesting a common mechanism of action. Comparison of the dimer
interfaces of PfFeSOD with the human manganese-dependent superoxide dismutase
reveals a number of differences, which may underpin the design of
parasite-selective superoxide dismutase inhibitors.
|
 |
|
|
|
|
 |